Craig Chambliss
About Craig Chambliss
Craig C. Chambliss is the President, CEO, and Co-Founder of Neurelis, with over 30 years of experience in the biopharma and drug delivery sectors, specializing in rare central nervous system diseases and epilepsy.
Craig C. Chambliss - President and CEO of Neurelis
Craig C. Chambliss is the President and CEO of Neurelis, an organization he co-founded in 2007. With three decades of experience in the biopharma and drug delivery industries, Chambliss has played a pivotal role in advancing treatments for rare diseases of the central nervous system and epilepsy. Under his leadership, Neurelis has obtained over $300 million in funding, establishing itself as a fully integrated organization.
Extensive Experience in Biopharma and Drug Delivery
Craig C. Chambliss has accumulated 30 years of expertise in biopharma and drug delivery, with a particular focus on rare diseases affecting the central nervous system and epilepsy. His career began at Bristol Myers Squibb in pharmaceutical sales, subsequently joining Alza Pharmaceuticals. At Alza, he held various sales and marketing roles before moving to Elan Pharmaceuticals as Director of Business Development for CNS assets.
Leadership in Company Transformations and Acquisitions
Chambliss has a notable history of steering companies towards significant transformations and successful acquisitions. At NextWave Pharmaceuticals, as Chief Business Officer, he repositioned the company to focus on CNS, raising $45 million in Series C financing and leading to the company's acquisition by Pfizer for over $700 million in 2012. As part of Questcor Pharmaceuticals from 2005-2007, he was integral in transitioning the company to a CNS focus and relaunching Acthar Gel.
Launch of Xcel Pharmaceuticals and Accomplishments
In 2001, Craig C. Chambliss co-founded Xcel Pharmaceuticals, a CNS start-up concentrating on epilepsy and seizure emergencies. He led the commercial operations and oversaw the successful launch of Diastat (diazepam rectal gel). In 2005, Xcel Pharmaceuticals was acquired by Valeant Pharmaceuticals for $280 million, highlighting the successful growth and strategic direction under Chambliss’s leadership.
Educational Background in Finance and Accounting
Craig C. Chambliss holds a Bachelor of Science in Finance and a Bachelor of Science in Accounting from Missouri State University. His educational foundation in finance and accounting has evidently supported his strategic leadership roles and successful business developments across multiple organizations in the biopharma sector.